CLL Society believes that every immunocompromised individual, including those with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), regardless of treatment status, should experience easy access to the life-saving pre-exposure prophylaxis therapy or PreP, Evusheld. Evusheld is an important therapy for the immunocompromised community as it offers these individuals a level of protection against a COVID-19 infection that they do not adequately obtain through the SARS-CoV-2 vaccine due to their inability to respond with antibody production adequately.
It is critically vital that Evusheld continues to be made readily available in every healthcare practice across the country, which is why CLL Society has been actively working with the US Administration for Strategic Preparedness & Response (ASPR) to ensure this is a reality. ASPR recently interviewed CLL Society Executive Vice President and Chief Medical Officer Dr. Brian Koffman to share his personal experience receiving the monoclonal antibody combination and advocate for its importance to be provided for every immunocompromised individual.
The ASPR webpage on Evusheld is targeted at a healthcare provider audience to ensure providers at practices of every scale are aware of the benefits of Evusheld and what demographic should be receiving it. In addition, CLL Society is proud to have our own Dr. Koffman featured on this page, supporting the effort to help ensure this drug is made available to all individuals across the United States who need it.
Watch Dr. Koffman’s video with ASPR below:
To learn more about ASPR’s efforts to educate healthcare providers and increase access to Evusheld, visit the ASPR webpage on Evusheld. You will also find CLL Society’s Dr. Koffman’s video on this webpage alongside fellow immunocompromised patients and healthcare providers speaking on the importance of Evusheld.